Core Viewpoint - The stock price of Lai Kai Pharmaceutical-B (02105) increased by approximately 5.95% to HKD 14.24 following the announcement that the FDA has accepted the IND application for LAE118, a new drug developed by the company [1][5]. Group 1: Company Announcement - Lai Kai Pharmaceutical announced that the FDA has accepted the clinical trial application (IND) for LAE118 on January 14 [1][5]. - LAE118 is a novel PI3Kα pan-mutant selective inhibitor developed by the company, aimed at treating patients with PIK3CA mutations in solid tumors [1][5]. - PI3Kα mutations are commonly found in breast cancer, colorectal cancer, lung cancer, endometrial cancer, and other cancer patients [1][5]. Group 2: Market Reaction - Following the announcement, Lai Kai Pharmaceutical's stock price saw an initial increase of nearly 7% [1][5]. - The trading volume reached HKD 15.6168 million at the time of reporting [1][5].
来凯医药-B早盘涨近6% LAE118新药临床试验申请获FDA受理